Literature DB >> 12161011

Breast cancer: from estrogen to androgen receptor.

S Andò1, F De Amicis, V Rago, A Carpino, M Maggiolini, M L Panno, M Lanzino.   

Abstract

To investigate the link existing between androgens and human breast cancer, the hormonal milieu present in pre- and post-menopausal women has been translated in an in vitro model utilizing a hormone dependent breast cancer cell line MCF-7 exposed to DHEA, DHEAS, androstenediol, T, DHT with or w/o E(2). DHEAS and androstenediol stimulate the growth of MCF-7 cell line but reduce cell proliferation induced by E(2) (1 nM). T and DHT (1-100 nM) instead inhibit MCF-7 cell proliferation independently on E(2) presence. When we focused our study on the most powerful androgen, DHT alone (100 nM) consistently inhibits MCF-7 cell proliferation by 50% of the basal growth rate and counteracts E(2) proliferative action by 68%. These data correlate well with cell cycle analysis showing an enhanced number of cells in G(0)/G(1) phase after 6 days of DHT treatment. Upon prolonged DHT exposure, Western blotting analysis shows a markedly increased AR content, while immunohistochemistry indicates that it was mostly translocated into the nucleus. So we assumed that the enhanced activation of the AR might inhibit MCF-7 cells proliferation. This assumption is corroborated by the fact that the inhibitory effects induced by DHT on MCF-7 cell proliferation are abrogated in the presence of hydroxyflutamide. Therefore to better investigate the role of AR in inhibiting E(2) action at genomic level, MCF-7 cells were transiently cotransfected with the reporter plasmid XETL carrying firefly luciferase sequence under the control of an estrogen responsive element and the full length AR or with an AR carrying a mutation (Cis 574-->Arg 574) which abolishes its binding to DNA. The over-expression of the AR markedly decreases E(2) signalling which furthermore appears inhibited by simultaneous exposure to DHT but reversed by addition of hydroxyflutamide. The inhibitory effect was no longer noticeable when MCF-7 cells were cotransfected with XETL and the mutant AR. Taken together these data demonstrate that gonadal androgens antagonize MCF-7 proliferation induced by E(2). This seems to be related to the inhibitory effects of the over-expressed AR on E(2) genomic action. Copyright 2002 Elsevier Science Ireland Ltd.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12161011     DOI: 10.1016/s0303-7207(02)00105-3

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  33 in total

1.  A human-derived prostate co-culture microtissue model using epithelial (RWPE-1) and stromal (WPMY-1) cell lines.

Authors:  Matthew P Dent; Samantha J Madnick; Susan Hall; Marguerite Vantangoli Policelli; Chloe Bars; Hui Li; Ali Amin; Paul L Carmichael; Francis L Martin; Kim Boekelheide
Journal:  Toxicol In Vitro       Date:  2019-05-30       Impact factor: 3.500

Review 2.  Androgens in human breast carcinoma.

Authors:  Takashi Suzuki; Yasuhiro Miki; Kiyoshi Takagi; Hisashi Hirakawa; Takuya Moriya; Noriaki Ohuchi; Hironobu Sasano
Journal:  Med Mol Morphol       Date:  2010-08-04       Impact factor: 2.309

3.  Inhibition of cyclin D1 expression by androgen receptor in breast cancer cells--identification of a novel androgen response element.

Authors:  Marilena Lanzino; Diego Sisci; Catia Morelli; Cecilia Garofalo; Stefania Catalano; Ivan Casaburi; Claudia Capparelli; Cinzia Giordano; Francesca Giordano; Marcello Maggiolini; Sebastiano Andò
Journal:  Nucleic Acids Res       Date:  2010-04-26       Impact factor: 16.971

4.  Cooperative signaling between Wnt1 and integrin-linked kinase induces accelerated breast tumor development.

Authors:  Arusha Oloumi; Mykola Maidan; Frances E Lock; Howard Tearle; Steven McKinney; William J Muller; Samuel A J R Aparicio; Shoukat Dedhar
Journal:  Breast Cancer Res       Date:  2010-06-21       Impact factor: 6.466

5.  5α-Dihydrotestosterone regulates the expression of L-type calcium channels and calcium-binding protein regucalcin in human breast cancer cells with suppression of cell growth.

Authors:  Ricardo Marques; Carina G Peres; Cátia V Vaz; Inês M Gomes; Marília I Figueira; Elisa Cairrão; Ignacio Verde; Cláudio J Maia; Sílvia Socorro
Journal:  Med Oncol       Date:  2015-08-09       Impact factor: 3.064

Review 6.  Minireview: The androgen receptor in breast tissues: growth inhibitor, tumor suppressor, oncogene?

Authors:  T E Hickey; J L L Robinson; J S Carroll; W D Tilley
Journal:  Mol Endocrinol       Date:  2012-06-28

7.  ARA67/PAT1 functions as a repressor to suppress androgen receptor transactivation.

Authors:  Yanqing Zhang; Yue Yang; Shuyuan Yeh; Chawnshang Chang
Journal:  Mol Cell Biol       Date:  2004-02       Impact factor: 4.272

8.  Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells.

Authors:  Francesca De Amicis; Janagi Thirugnansampanthan; Yukun Cui; Jennifer Selever; Amanda Beyer; Irma Parra; Nancy L Weigel; Matthew H Herynk; Anna Tsimelzon; Michael T Lewis; Gary C Chamness; Susan G Hilsenbeck; Sebastiano Andò; Suzanne A W Fuqua
Journal:  Breast Cancer Res Treat       Date:  2009-06-17       Impact factor: 4.872

9.  Radiolabeled 5-iodo-3'-O-(17beta-succinyl-5alpha-androstan-3-one)-2'-deoxyuridine and its 5'-monophosphate for imaging and therapy of androgen receptor-positive cancers: synthesis and biological evaluation.

Authors:  Zbigniew P Kortylewicz; Jessica Nearman; Janina Baranowska-Kortylewicz
Journal:  J Med Chem       Date:  2009-08-27       Impact factor: 7.446

10.  The gad2 promoter is a transcriptional target of estrogen receptor (ER)alpha and ER beta: a unifying hypothesis to explain diverse effects of estradiol.

Authors:  Edward D Hudgens; Lan Ji; Clifford D Carpenter; Sandra L Petersen
Journal:  J Neurosci       Date:  2009-07-08       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.